Biomarin Pharmaceutical Inc (BMRN)
66.00
-0.60
(-0.90%)
USD |
NASDAQ |
Nov 04, 16:00
66.78
+0.78
(+1.18%)
After-Hours: 06:37
Biomarin Pharmaceutical Free Cash Flow: 300.88M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | 300.88M |
| June 30, 2024 | 212.80M |
| March 31, 2024 | 163.21M |
| December 31, 2023 | 51.65M |
| September 30, 2023 | 31.29M |
| June 30, 2023 | 40.91M |
| March 31, 2023 | 21.77M |
| December 31, 2022 | 44.36M |
| September 30, 2022 | 40.76M |
| June 30, 2022 | -4.394M |
| March 31, 2022 | 23.95M |
| December 31, 2021 | 185.31M |
| September 30, 2021 | 165.24M |
| June 30, 2021 | 154.60M |
| March 31, 2021 | 92.32M |
| December 31, 2020 | -52.15M |
| September 30, 2020 | -2.405M |
| June 30, 2020 | -33.74M |
| March 31, 2020 | -89.02M |
| December 31, 2019 | -115.14M |
| September 30, 2019 | -104.35M |
| June 30, 2019 | -141.73M |
| March 31, 2019 | -137.07M |
| December 31, 2018 | -124.41M |
| September 30, 2018 | -156.98M |
| Date | Value |
|---|---|
| June 30, 2018 | -158.51M |
| March 31, 2018 | -131.12M |
| December 31, 2017 | -207.98M |
| September 30, 2017 | -234.48M |
| June 30, 2017 | -266.76M |
| March 31, 2017 | -309.09M |
| December 31, 2016 | -376.22M |
| September 30, 2016 | -494.09M |
| June 30, 2016 | -505.03M |
| March 31, 2016 | -482.17M |
| December 31, 2015 | -447.15M |
| September 30, 2015 | -329.17M |
| June 30, 2015 | -315.49M |
| March 31, 2015 | -319.03M |
| December 31, 2014 | -187.48M |
| September 30, 2014 | -174.56M |
| June 30, 2014 | -163.53M |
| March 31, 2014 | -128.77M |
| December 31, 2013 | -122.53M |
| September 30, 2013 | -85.69M |
| June 30, 2013 | -63.79M |
| March 31, 2013 | -57.47M |
| December 31, 2012 | -26.96M |
| September 30, 2012 | -115.25M |
| June 30, 2012 | -161.97M |
Free Cash Flow Range, Past 5 Years
-115.14M
Minimum
Dec 2019
300.88M
Maximum
Sep 2024
61.61M
Average
40.83M
Median
Free Cash Flow Benchmarks
| Merck & Co Inc | 13.15B |
| Bristol-Myers Squibb Co | 13.80B |
| Alnylam Pharmaceuticals Inc | 16.06M |
| Bioventus Inc | 8.443M |
| Moderna Inc | -3.979B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 221.48M |
| Cash from Investing (Quarterly) | -16.16M |
| Cash from Financing (Quarterly) | -499.12M |
| Free Cash Flow Per Share (Quarterly) | 1.016 |
| Free Cash Flow to Equity (Quarterly) | 694.63M |
| Free Cash Flow to Firm (Quarterly) | 200.30M |
| Free Cash Flow Yield | 2.32% |